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SUMMARY.-In tobacco carcinogenesis research, considerable attention has
been paid to the choice of the bioassay. The ideal system should simulate the
human smoking setting as closely as possible and should utilize tissue of a type
similar to that found at the sites where the tobacco smoke-related cancers
originate in man. However, although certain inhalation experiments in the
laboratory meet these requirements to some extent, they are generally time-
consuming and difficult to evaluate and since they usually have to be performed
on large animals, are exttemely costly when used for the identification of the
actual tumorigenic agents in the smoke.
The present article examines the reasons why mouse skin is a useful bio-
assay. The system has enabled investigators to identify tumor initiators and
accelerators and to determine that the major tumor promoters reside in the
weakly acidic portion of tobacco smoke. The mouse skin bioassay demon-
strated that with significant inhibition of the pyrosynthesis of alkylated and
non-alkylated polynuclear aromatic hydrocarbons, the tumorigenicity of the
"tar" will also decrease significantly.
ONE aim in tobacco carcinogenesis is to correlate experimental findings with
human data while recognizing the limitations inherent in animal model studies
(Wynder and Hoffmann, 1967). Experimental tobacco carcinogenesis was begun
as a result of observations on man which have led to the conclusion that tobacco
usage is causative in the induction of cancers of the lung, oral cavity, and vocal
cords- (Royal College of Physicians, 1962; W.H.O., 1964; Advisory Committee
Surgeon General, 1964; U.S. Public Health Service, 1969). Epidemiological
evidence has shown that tobacco smoke is carcinogenic to the ciliated columnar
epithelium ofthe bronchus and the squamous epithelium ofthe vocal cord and the
oral mucosa. Pathological studies have indicated that the ciliated columnar
epithelium of bronchi converts to squamous epithelium prior to malignant trans-
formation (Auerbach et at., 1961). Thus, based on human data, the squamous
epithelium should be considered as our primary target tissue.
Experimental Findings
Choice of an animal model
When an environmental agent has been demonstrated to be carcinogenic to
man, animalstudies areindicated toexplorethepossible mechanismsleadingtothe
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human data. Beside the choice ofthe most suitable animal, the type oftissue to
be exposed, and the route of application also require consideration.
In experimental tobacco carcinogenesis we have primarily used the squamous
epithelium ofthe skin because it is comparable to the type ofcells affected in man
and because it iseasily accessible, thus permittingthe use oflarge groups ofanimals
for bioassays. Since highly-differentiated ciliated columnar epithelium requires
conversion into squamous epithelium prior to any malignant change, this type of
tissue should be considered primarily when studying squamous metaplasia.
Based on human smoking habits, contact application is the preferable form of
exposure for the laboratory experiment. Ideally, tobacco smoke should impinge
directly on to the epithelium, as when man inhales tobacco smoke. It is on this
point that human smoking is most difficult, though not impossible, to duplicate
experimentally. We hesitate to acceptrepeated subcutaneous injections of" tar "
as a usefulbioassaytechniquefortobacco carcinogenesisandagreewiththecautious
interpretation of such experiments by the Food Protection Committee of the
National Academy of Sciences (1960) and the FAO/WHO Expert Committee
(1961).
Skin Carcinogenesis
Tobacco smoke condensate has been proved to be a complete carcinogen to the
skin of mice and rabbits when applied undiluted and in a variety of solvents
(Wynder and Hoffmann, 1967). A dose response curve has been established for
tobacco " tars " similar to that obtained for carcinogenic polynuclear aromatic
hydrocarbons (PAH) (Wynder and Hoffmann, 1967; Day, 1967; Bock, 1968). The
failure to induce higher tumor yields in the mice at risk as has been reported may
be due to the toxicity ofthe " tars " that limits the total dose that can be given,
problems associated with absorption or due to their relatively weak carcinogenic
activity.
Testing tobacco smoke by the impingement ofthe smoke with a capillary press
(Seehofer and Hanszen, 1965) ontothe skin ofmice is inprogressin ourlaboratory.
In this experiment the smoke of two cigarettes, containing about 52 mg. moist
particulate matter, is applied three times per week. At the end ofthe eighteenth
month, no skin tumors have been observed (Wynder and Hoffmann, 1970,
unpublished data). The complexity of this experiment involving adequate dose
delivery as well as the irritation associated with compressing the smoke on to the
skin makes this model oflimited usefulness.
Tumor initiation
Tumor initiators have been identified only in the neutral fraction of tobacco
"tar " and its subfractions B and BI (Wynder and Hoffmann, 1968; Fig. 1 and 2).
We have recently completed a further fractionation ofBI by distribution between
solvent pairs into 5 subfractions (Hoffmann and Wynder, 1970). The PAH
subfraction BIH (0.08% of whole " tar ") was separated by an additional column
chromatography into 80 subfractions (Fig. 3). The best known carcinogen in BI,
BIH and in its subfractions 72-78 is benzo(a)pyrene (BaP). By itself, this com-
pound cannot account for the total carcinogenic activity ofthe whole " tar ", nor
for the initiating activity of the " tar "; yet it represents a good indicator of the
carcinogenic activity of different tobacco " tars " (Hoffmann and Wynder, 1968;
Fig. 4).
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FIG. 1.-Fractionation of cigarette smoke condensate and relative tumorigenic activities of
condensate fractions and subfractions (Wynder and Wright, 1957; Wynder and Hoffmann,
1967).
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FIG. 2.-Fractionation of neutral subfraction B of cigarette smoke condensate (Wynder and
Hoffmann, 1967).
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FiG. 3.-Tumor initiating activities of BIh subfractions.
Initiator: Each ofthe BIh subfractions was applied in 10 subdoses in the amount as isolated from
2 08 kg. of dry " tar '.
Promoter: 1-0% croton oil (10 month application).
Control: 1* 0% croton oil only; 100 mice.
Experimental Groups BIh, 1-BIh, 80: 20 mice, each.
A-Line: Fractions with values on/or above have significantly higher tumor initiating activity than
the control (P < 0-05).
B-Line: Fractions with values on/or above have strong tumor initiating activity and significantly
higher activity than fractions with values on A-Line (P < 0 05).
Data from Hoffmann and Wynder (1970).
Clearly, in BI there are probably other PAH carcinogens, N-heterocyclic
carcinogens, and possibly new and as yet unidentified carcinogens, especially
alkylated PAH, as well as non-carcinogenic components that add to the activity of
BaP. One such group ofsubstances so far biologically unexplored, is the " tumor
accelerators ".E. L. WYNDER AND D. HOFFMANN
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FIG. 4.-Bioassay of cigarette smoke condensates tumorigenicity and BaP.
The linear-regression line was calculated by the least squares method.
Values are from published data (Hoffmann and Wynder, 1968, 1970; Wynder and Hoffmann,
1967, 1969 and 1970).
Tumor accelerators*
We define accelerators as components which exhibit neither carcinogenic
activity nor tumor initiating activity, nor tumor promoting activitywhile accelera-
ting the activity of complete carcinogens or of tumor initiators when applied
concurrently.
Up to now, we have only completed tests on three BI constituents as accelera-
tors: trans-4,4'-dichlorostilbene (DCS), 1-methylindole and 9-methylcarbazole
(Hoffmann andRathkamp, 1968; Hoffmann etal., 1969; HoffmannandRathkamp,
1970; Fig. 5). DCS is a major pyrolysis product of the most commonly used
tobacco insecticides, DDT and DDD. It is inactive as a complete carcinogen, and
Cl
H
I~~~~~~~~~~~
CH3 CH3
Ci
Trans 4, 4'-Dichlorostilbene 1- Methylindole 9- Methylcarbazole
(200 pg./100cig.) (42 pg./l00 cig.) (10jig./100cig.)
FIG. 5.-Accelerators oftumorigenic agents in cigarette smoke.
The values in parentheses represent the amount isolated from the mainstream smoke of 85 mm.
U.S. blended cigarettes without filter tip (Hoffmann and Rathkamp, 1968, 1970; Hoffmann et al.,
1969).
* The experimental methods used for the bioassay oftumorigenic agents were earlier described in
detail (Wynder and Hoffmann, 1967).
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also as a tumor initiator, and it does not increase the activity of BaP when fed
during the skin application of the carcinogen. However, the activity of BaP is
significantly enhanced when both agents are concurrently applied to mouse skin
(Hoffmann and Wynder, 1970; Fig. 6). 9-Methylcarbazole was first identified in
the active subfractions 61-66 (Fig. 3) which did not reveal the presence ofa known
tumor initiator. 9-Methylcarbazole acts as an accelerator when applied concur-
rently with BaP as a tumor initiator (Hoffmann and Wynder, 1970; Fig. 7).
I-Methylindole, present in subfractions 50-62, acts similarly as an accelerator.
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FiG. 6.-Tumor accelerating activity of trans-4,4'-dichlorostilbene.
D.C.S. diet = 0-05 in the standard food.
D.C.S. painting = 0.3% solution.
BaP painting = 0 003% solution (Hoffmann and Wynder, 1970).
BaP = benzo(a)pyrene; D.C.S. = trans-4,4'-dichlorostilbene.
Ofparticular interest is the actual biochemical mechanism by means ofwhich
components such as DCS and 9-methylcarbazole become tumor accelerators.
One can speculate that this mechanism is affected by the acceleration of the
carcinogen's diffusion through the cell membrane, by competitive reactions on
macromolecular cell constituents, by changing of the cell respiration, or by some
other mechanism. Some ofthese possibilities are presently under investigation in
our laboratory.
Tumwr promoters
Tobacco smoke condensate and tobacco extracts both possess tumor promoting
activity (Wynder and Hoffmann, 1969; Bock et al., 1969). It remains to be
shown whether the promoters in tobacco and tobacco smoke have different
configurations or whether some distil, or sublimate, unchanged into the main-
stream smoke.
Studies with smoke condensate revealed a low tumor promoting activity for
"tars " obtained from cigarettes made entirely from tobacco stems (Wynder and
50
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FIG. 7.-Tumor accelerating activity of 9-methylcarbazole.
BaP initiation = 5 jtg. in 25 pl. 10 subdoses of a 0-02% solution.
9-MC initiation - 0.5% solution.
C.O. promotion = 1-0% solution.
9-MC promotion = 0.5% solution (Hoffmann and Wynder, 1970).
BaP = benzo(a)pyrene; 9-MC = 9-methylcarbazole; C.O. = croton oil.
Hoffmann, 1969; Fig. 8). This finding is not entirely unexpected, as stems have a
very high cellulose content and are practically free of terpenes.
At present, no specific tumor promoter has been identified which may be
responsible for the tumor promoting activity in the extract or the condensate.
Fractionation studies suggest that the major tumor promoters reside in the weakly
acidic (phenolic) and the acidic fractions (Roe et al., 1959; Wynder and Hoffmann
1961; Bock et al., 1969).
Multiple Stage Carcinogenesis
The foregoing indicates that in terms ofbronchial epithelium, tobacco carcino-
genesis involves a series of biological stages. Initially, ciliated columnar tissue
converts into squamous tissue, as has been shown by in vitro and in vivo studies
(Wynder and Hoffmann, 1967). The conversion can be brought about by a
variety of agents, such as gaseous components, particulate matter, bacterial and
viral infections (Kotin and Wisely, 1963; Wynder et al., 1968). Factors which
alter the natural defense mechanism of the respiratory epithelium such as ciliary
action and mucus flow may thus be of etiological importance. The relative
importance of the gaseous and particulate phases to the inhibition of ciliar move-
ment and mucus flow remains to be determined. Here, we need to remember that
between 60% to 80% of the major known ciliatoxic volatile components are
retained in the oral cavity during inhalation (Dalhamn et al., 1968).
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FIG. 8.-Tumor promoting activities of cigarette smoke condensate.
Data from Wynder and Hoffmann, 1969.
Recent studies by Auerbach and Hammond (1970) have indicated that the
carcinogenic activity ofcigarette smoke to the bronchial epithelium ofdogs can be
similarly reduced by either smoking only half the number of cigarettes or by
smoking the same number of cigarettes, but with cellulose acetate filters which
deliver about halfthe amount ofparticulate matter ofthe cigarettes without filter
tips made from the same tobacco blend. This latterresult suggests that the major
carcinogenic activity of cigarette smoke resides in the particulate phase, although
cellulose acetate filters are known to reduce the concentration of certain acids in
the smoke (Hoffmann and Wynder, 1963; Spears, 1963; Williamson and Allman,
1964; George and Keith, 1967).
Carcinogenicity has so far not been demonstrated for the volatile components
of cigarette smoke.
Oral Cavity Tobacco Carcinoqenesis
Compared with the use ofmouse or rabbit skin, the oral cavity ofthese animals
has only received limited attention as a test site for tobacco carcinogenesis. One
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reason is the difficulty of " tar " application. Active mucus production and the
passage offood and water causes the " tar " to be less likely to remain localized in
the oral cavity, so that there is insufficient contact time for carcinogens at the test
site. It is thus not surprising that most experiments done in this area have been
negative (Wynder and Hoffmann, 1967). It should be recalled, however, that the
mucus-producing epithelium is susceptible to tobacco carcinogens, as shown by
studies in which " tar " was applied to the cervix ofmice (Koprowska and Bogacz,
1959). In this setting, the " tar " was apparently localized for a sufficient length
of time and in sufficient quantities to exert its carcinogenic effect.
Tobacco Carcinogenesis of the Respiratory Tract
The difficulties ofreproducing cancer ofthe respiratory epithelium in an experi-
mental setting have been well reported (Kennaway and Lindsey, 1958; Kotin and
Wisely, 1963; Wynder and Hoffmann, 1967). Since Essenberg's studies in 1952,
passive inhalation experiments using the bronchial epithelium as the test site have
not significantly contributed to the carcinogenic bioassay of tobacco products.
One observation is that the defensive action ofthe mucus layer which is propelled
upward by the cilia, protects the bronchial epithelium from toxic agents in the
respiratory environment. Furthermore, nature has provided man with additional
protection in that the nasal passage acts not only by conditioning the inhaled air-
stream, but also by acting as a filter. Such filtration systems are especially well
developed in laboratory animals, all of which are obligatory nose breathers
(Wynder et al., 1968; Fig. 9). These basic anatomic considerations must be
appreciated before undertaking long-term studies using the lung as the test site.
Since the larynx of an experimental animal possesses no ciliated columnar epi-
thelium, more prolonged deposition ofparticulate matter may occur here than in
the bronchus. Recent studies by Dontenwill indicated that passive smoking may
lead to malignant changes in this anatomical region (Dontenwill, 1969). He
reported papillary tumors as pre-cancerous epithelial lesions in the larynx of
hamsters exposed to the passive inhalation of cigarette smoke while no significant
alterations were observed in the bronchial epithelium ofthe hamsters.
This presentation is limited to a discussion ofsquamous cell cancer and does not
include adenomas or adenocarcinoma. The reason for this omission is that the
adenomatous type ofmouse tumor bears no resemblance to the tumors responsible
for most oflung cancer occurring in man (Kuschner, 1968).
Squamous cell cancer of the bronchus can be produced by applying high
concentrations ofBaP (5 mg.) or 3-methylcholanthrene (MC; 5 mg.), with a carrier
such as iron dust (Saffiotti et al., 1968), or with Freund's adjuvent (Yashuria, 1967),
or by applying BaP as a mist with SO2 (Laskin and Kuschner, 1967). The
relatively high dosage levels of carcinogenic PAH and the necessity for other
agents to circumvent the protective barrier of the respiratory epithelium indicate
that a weak carcinogen such as tobacco smoke is unlikely to produce a significant
EXPLANATION OF PLATE
Fia. 9. Frontal sections through the nasal cavity of four mammals. Rat and guinea pig:
through olfactory portion. Rabbit: through respiratory portion. (The human does not
have similar anatomical separation.)
From Wynder and Hoffmann, 1967.
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numberoftumorsbyitself. Inaddition, the concentrationsinwhichtobaccosmoke
can be administered are limited by its toxic effect and by the nasal defenses.
Before undertaking further passive inhalation experiments, it would be advisable
to determine the amount of " tar " that actually enters the lung.
On the basis of nicotine determinations (20 ,ug. per g. of lung after smoke
exposure)-which physicochemically cannot be regarded as an appropriate indi-
cator for particulate matter in this setting (Stedman, 1968)-the exposure is
clearly far below the " tar " levels that could be expected to produce cancer
(Dontenwill et al., 1966). Even by eliminating or reducing the mucous defenses
through viral or bacterial infection, one does not reach the dosage necessary to
induce significant malignant transformation of the respiratory epithelium.
Tobacco " tar " can, of course, be applied directly through a bronchoscope to the
respiratoryepithelium oflarger animals, such as dogs. However, the experimental
difficulties and cost of such efforts are apparent. Rockey and Speer (1966) have
produced cancer in situ in this way, although they were not able to produce
invasive cancer. Extensive active smoke inhalation experiments using dogs in
Auerbach's laboratory entails having the animals smoke cigarettes through a
tracheostomy (Auerbach et al., 1967). This group found hyperplastic and meta-
plastic lesions in the dogs similar to those describedfor man (Auerbach et al., 1961).
Recently, Auerbach and Hammond (1970) reported the production of early
squamous cancer in the bronchus ofthese " smoking " dogs. The major problems
ofthis type of study are early death from emphysema and emboli and, obviously,
the cost.
One way in which this experimental setting differs from the human situation is
that there is no allowance for the deposition of smoke particles and the filtration
effects exerted by the upper respiratory tract. This type ofexperiment, however,
appears to be most pertinent in studying the pathological effects offresh cigarette
smoke on the lungs ofanimals. This method could be usedto compare the effect of
different types of cigarettes as well as different filtration systems. Obviously, if
one wants to obtain malignant tumors, long-term tests are necessary, though in a
shorter time period, histological changes may provide prognostic leads in terms of
subsequent malignant transformations.
Summwtion ofExperimental Findings
We conclude that passive inhalation experiments are not promising, except
when the larynx is used as the test site, while active inhalation experiments, such
as those described in dogs, will show positive results, although they are obviously
time consuming and costly.
The advantage of mouse skin is that it is responsive to tumorigenic substances
in relatively small doses; it responds only to carcinogens and not to non-specific
physical agents such as may be the case in sarcoma formation; and it involves
squamous epithelium, which even in the respiratory epithelium must be formed
before malignant transformation can take place. It appears reasonable to assume
that the response of a relatively simple cell, such as the epithelial cell, to carcino-
genic stimuli is-similar in different sites, at-least of the same species, as has been
shown with PAH carcinogens in mice. Mouse skin screenings also permit tests on
large numbers of animals, thus enabling us to establish statistically significant
differences in the biological activity of various tobacco products.
At present, the tumor response induced withtobacco "tar " on the skin ofmice
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anidrabbits is anliml)ortant, ifnot the only, souirce ofour knowledge about initiiating,
accelerating and promotiiig agents in tobacco products, thus leading to steps that
can conitribute to a reduction of these agents in tobacco smnoke.
Hlutman ELidence
Finally, we need to comie back to muani. For t,he epidemiologist, mlla is quasi aln
experimental animal. The " randomn selection " of imian, however, inay be con-
sidered as a problem by some investigators. Howtever, mnan can be studied by such
variables as smoking habits, the blend, " tar " and nicotine content, and the type
of filters on the cigarettes he smokes. AWNe need to recognize that certain human
habits such as tobacco smoking and chewing are difficult, if not impossible, to
duplicate in the laboratory setting. It is for this reason that w%e .must utilize the
most practical system available. Although we suggest this should be the imouse
skini, we should continue the searclh for otlher, possibly better, bioassay systems.
Of other systems presently used, Dontenwill's passive inhlialatioln system, using a
fresh air/smoke mixture with thLe hamster larynx as the test site, and particularly
Auerbach's active inihalation system with dogs, appear to be the most promisinig.
'e are interested in knowiing lhow certain tobacco usages may affect thle risk to
smiokers ofdeveloping cancer. The difference in the risk ofdeveloping lung, vocal
cord or mouth cancer between pipe anid cigar smokers on the one hand, and
cigarette smokers on the otlher, appears to reflect, primarily, differences in inhala-
tioln practices. WA'hen inhlialation does not play a role. as for cancer of the mouth.
the risk is similar among cigar, pipe and cigarette smokers (Fig. 10).
AWhen considering cigarettes of different types, epidemiological evidenice is
Ca. Buccal Cavity Ca. Larynx Ca. Lung
(Source U. S. Veterans Study, 1966)
FIG.,. 10. Alortality iatios by sito for cturrent eigarette, pipe aniidlor cigar smokers.
From Kahn (1966). Figures in parentheses represent inumber of patients il each group.
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difficult to evaluate because it isinfluenced by so manyvariables. For example, in
England and in Finland, flue-cured tobaccos are principally used; while in France,
smokers prefer air-cured tobaccos. The present-day lung cancer rates in these
countries are in part a reflection of the per capita cigarette consumption three or
four decades ago. Of course, the differences in lung cancer rates in various coun-
tries can also be a reflection ofdifferences in the practice ofthe inhalation and the
number ofpuffs taken per cigarette, the relative rates ofother causes ofdeath, as
well as the quality ofvital statistics. However, the data certainly do not suggest
that air-cured tobacco, with its relatively high nitrate content, is more carcino-
genic to man than flue-cured tobacco with its low nitrate content (Neurath and
Ehmke, 1964; Lipp and Dolberg, 1964; Hoffmann and Wynder, 1968). The sug-
gestion that fresh smoke of high nitrate tobacco contains N-nitrosamines has not
yet been proven in the laboratory (Neurath, 1967).
An epidemiological lead of paramount importance is the relative risk of lung
cancer among smokers of low and high " tar " cigarettes. Existing data are
difficult to evaluate, because all current lung cancer patients began smoking high
" tar " regular cigarettes. Hammond's (1966) data on ex-smokers suggest that
among heavy smokers the risk oflung cancer declines to the level ofnon-smokers
after ten years. In a current study we are examining lung cancer patients who
have smoked filter cigarettes for ten years or more and comparing their smoking
habits with lung cancer patients who have smoked regular cigarettes only (Wynder
et al., 1970). The former group smoked more cigarettes-an average of43 per day
-than the smokers ofregular cigarettes-35 per day. At the same time, there is
no difference in the number of cigarettes smoked in the control non-cancer groups
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FIG. 11.-Average TPM and nicotine content in the mainstream smoke of the ten best-selling
American cigarettes.
The data are compiled from various reports: Consumer'8 Report, Reader8' Digest, Federal Trade
Commi8sion Report, and the results have been converted to correspond to the standards employed by
the Federal Trade Coommission.
TPM = total particulate matter.
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by the users of regular cigarettes and individuals who smoked filter cigarettes for
more than ten years; both groups averaging 22 cigarettes daily. The data indicate
that a filter or low " tar " cigarette smoker has to smoke more cigarettes than a
smoker ofregular or high " tar " cigarettes to develop lung cancer. The long-term
filter cigarette smokers did not include individuals reporting the use of charcoal
filters. Since in the gas phase, only some volatile weak acidic components are
reduced by the cellulose acetate filters most commonly used in filter cigarettes,
these results are in line with the concept that the main carcinogens are contained in
the particulate matter (" tar "). There has been a definite decrease in the " tar "
and nicotine yields of cigarettes in the United States in the last twenty years
(Fig. 11). Our data suggest that the probability for an individual to develop lung
cancer should be lower for today's smokers than for smokers in 1950, unless they
smoke more cigarettes than the individual of twenty years ago.
Epidemiological studies along these lines need to be continued and expanded to
examine various types of cigarettes and filters and should be carried out on a
standardized basis in different countries to afford appropriate international
comparisons. Today, the evidence that a specific agent increases the risk ofcancer
in man has to be obtained from man himself, and the proof that a new type of
tobacco product is less carcinogenic must alsobe derivedfrom man. However, it is
the task ofthelaboratoryscientisttostudythemechanism oftobacco carcinogenesis
as it relates to different types of tissues, to identify the tumorigenic agents in
tobacco smoke, and to develop methods for their reduction.
This work was supported by American Cancer Society Grant E-231.
REFERENCES
ADVISORY COMMITTEE TO THE SURGEON GENERAL OF THE PUBLIc HEALTH SERVICE-
(1964) Publ. Hlth Serv. Publs, Wash., No. 1103.
AuERBACH, 0. AND HAMMOND, E. C.-(1970) 'Effects ofCigarette Smoking upon Dogs
Rep. Am. Cancer Soc., Feb. 5, 1970.
AUERBACH, O., HAMMOND, E. C., KIRMAN, D., GARFINKEL, L. AND STOUT, A. P.-(1967)
Cancer, N.Y., 20, 2055.
AUERBACH, O., STOUT, A. P., HAMMOND, E. C. AND GARFINKEL, L.-(1961) NewEngl. J.
Med., 265, 253.
BOCK, F. G.-(1968) Natn. Cancer Inst. Monogr., 28, 53.
BOCK, F. G., SWAIN, A. P. AND STEDMAN, R. L.-(1969) Cancer Res., 29, 584.
DALHAMN, T., EDFORS, M. S. AND RYLANDER, R.-(1968) Archs envir. Hlth, 16, 831.
DAY, T. D.-(1967) Br. J. Cancer, 21, 56.
DONTENWILL, W.-(1969) 'Investigations of Cigarette Smoke Inhalation on Experi-
mental Animals'. Presented at U.I.C.C. Conf. on Carcinogenesis by Inhalation
with Special Reference to Cigarette Smoke, Lausanne, Switzerland. June 20-22,
1969.
DONTENWILL, W., RECKZEH, G. AND STADLER, L.-(1966) Beitr. Tabakforsch., 3, 438.
ESSENBERG, J. M.-(1952) Science, N.Y., 116, 561.
FAO/WHO EXPERT COMMITTEE ON FOOD ADDITIVES-(1961) Tech. Rep. Ser. Wld Hlth
Org., No. 220.
FOOD PROTECTION COMMITTEE, NATIONAL ACADEMY OF SCIENCES-(1960) Natn. Acad.
Sci. Publ., No. 745.
GEORGE, T. W. AND KEITH, C. H.-(1967) In 'Tobacco and Tobacco Smoke, Studies in
Experimental Carcinogenesis'. Edited by E. L. Wynder and D. Hoffmann.
New York (Academic Press) p. 577.BIOASSAY SYSTEMS IN TOBACCO CARCINOGENESIS 587
HAMMOND, E. C.-(1966) Natn. Cancer Inst. Monogr., 19, 127.
HOFFMANN, D. AND RATHKAMP, G.-(1968) Beitr. Tabakforsch., 4, 201.-(1970) Analyt.
Chem., 42, 366.
HOFFMANN, D., RATHKAMP, G. AND NESNOW, S.-(1969) Analyt. Chem., 41, 1256.
HOFFMANN, D. AND WYNDER, E. L.-(1963) J. natn. Cancer Inst., 30, 67.-(1968) Natn.
Cancer Inst. Monogr., 28, 151.-(1970) Cancer, N.Y., in press.
KAHN, H. A.-(1966) Natn. Cancer Inst. Monogr., 19, 1.
KENNAWAY, E. L. AND LINDSEY, A. J.-(1958) Br. med. Bull., 14, 124.
KOPROWSKA, I. AND BOGACZ, J.-(1959) J. natn. Cancer Inst., 23, 1.
KOTIN, P. AND WISELY, D. V.-(1963) Prog. exp. Tumor Res., 3, 186.
KUSCHNER, M.-(1968) Am. Rev. resp. Dis., 98, 573.
LASKIN, S. AND KUSCHNER, M.-(1967) Presented at 60th Annual Meeting Air Poll.
Control Ass., Cleveland, Ohio, June 11-16, 1967.
LIrPP, G. AND D6LBERG, U.-(1964) Beitr. Tabakforsch., 2, 345.
NEURATH, G.-(1967) Experientia, 23, 400.
NEURATH, G. AND EHMKE, H.-(1964) Beitr. Tabakforsch., 2, 333.
ROCKEY, E. E. AND SPEER, F. D.-(1966) Int. Surg., 46, 520.
ROE, F. J. C., SALAMAN, M. H., COHEN, J. AND BURGAN, J. G.-(1959) Br. J. Cancer, 13,
623.
ROYAL COLLEGE OF PHYSICIANS-(1962) 'Smoking and Health'. London (Pitman
Med. Publ. Co.).
SAFFIOTTI, M., CEFIS, F. AND KOLB, L. H.-(1968) Cancer Res., 28, 104.
SEEHOFER, F. AND HANSZEN, D.-(1965) Beitr. Tabakforsch., 3, 291.
SPEARS, A.-(1963) Tobacco Sci., 7, 76.
STEDMAN, R. L.-(1968) Natn. Cancer Inst. Monogr., 28, 113.
U.S. PUBLIC HEALTH SERVICE-(1969) Publ. Hlth Serv. Publs, Wash., No. 1696.
WILLIAMSON, J. T. AND ALLMAN, D. R.-(1964) Beitr. Tabakforsch., 2, 263.
W.H.O. EXPERT COMMITTEE ON THE PREVENTION OF CANCER-(1964) Tech. Rep. Ser.
Wld Hlth Org., No. 276.
WYNDER, E. L. AND HOFFMANN, D.-(1961) Cancer, N.Y., 14, 1306.-(1967) 'Tobacco
and Tobacco Smoke. Studies in Experimental Carcinogenesis'. New York
(Academic Press).-(1968) Science, N.Y., 162, 862.-(1969) Cancer, N.Y., 24, 289.
WYNDER, E. L., MABUCHI, K. AND BEATTIE, E. J., JR.-(1970)J. Am. med. Ass., in press.
WYNDER, E. L., TAGUCHI, K., BADEN, V. AND HOFFMANN, D.-(1968) Cancer, N.Y., 31,
134.
WYNDER, E. L. AND WRIGHT, G.-(1957) Cancer, N.Y., 10, 255.
YASHURIA, K.-(1967) Acta path. jap., 17, 475.